An antibody-based drug for multiple sclerosis

July 20, 2016, Institut National de la Sante et de la Recherche Medicale
Demyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100. Credit: Marvin 101/Wikipedia

Inserm Unit U919, directed by Prof. Denis Vivien ("Serine Proteases and Physiopathology of the Neurovascular Unit") has developed an antibody with potential therapeutic effects against multiple sclerosis. The study, directed by Fabian Docagne and published in Brain, paves the way for a new strategy to control the disease.

Multiple sclerosis is a disease that affects the central nervous system, particularly the brain and spinal cord. It is the most common cause of neurological disability in young adults.

The disease is considered autoimmune since the , which is there to protect the body from external assault, attacks its own constituents. The cells of the immune system, particularly the lymphocytes, bring about the destruction of the myelin sheath that surrounds and protects the extensions (axons) of the neurons. This demyelination, which marks the beginning of axon degeneration, disrupts the transmission of nerve impulses. Lesions in the form of "plaques" are dispersed over the brain and spinal cord. They cause symptoms that vary greatly from one individual to another.

Usually, the disease is characterised by exacerbations, with the appearance of motor, sensory and cognitive disorders, followed by remission a few weeks later. But with the passage of years, these symptoms can progress to irreversible disability. Current treatments reduce the exacerbations and improve the quality of life of patients, but do not control the progression of the disease.

In order for the cells of the immune system circulating in the bloodstream to reach the central nervous system, they must penetrate the (haematoencephalic barrier) and blood-spinal cord barrier (haematomedullary barrier).

During previous work on a of stroke, the team from Inserm Unit 919 studied a factor involved in opening the blood-brain barrier, the NMDA receptor. In particular, they observed that blocking the interaction of this receptor with tPA (a member of the serine protease family) has beneficial effects associated with maintaining the integrity of the barrier.

In this study, the researchers developed a strategy for blocking the interaction of tPA with the receptor, in . In the laboratory, they developed a monoclonal antibody (Glunomab) directed against the specific site on the NMDA receptor to which tPA binds.

In cellular models of the human blood-brain and blood-spinal cord barriers, the use of this antibody prevented opening of the barrier under inflammatory conditions, limiting the entry of lymphocytes. The team then tested the therapeutic effects of the antibody in an experimental mouse model of multiple sclerosis. After intravenous injection of Glunomab, the progression of motor disorders (partial or total paralysis of the limbs), as assessed by a clinical score, was blocked. In these treated mice, this effect was associated with reduced infiltration of lymphocytes into the nervous tissue, and reduced demyelination.By thus preventing myelin destruction by the cells of the immune system, this strategy might represent a promising therapy for the control of multiple sclerosis.

A patent application has been filed on this work.

Explore further: Receptor may hold key to multiple sclerosis treatment

More information: Neuroendothelial NMDA receptors as therapeutic targets in experimental autoimmune encephalomyelitis, Brain, 20 July 2016.

Related Stories

Receptor may hold key to multiple sclerosis treatment

June 11, 2012
(Medical Xpress) -- A receptor recently discovered to control the movement of immune cells across central nervous system barriers (including the blood-brain barrier) may hold the key to treating multiple sclerosis (MS), a ...

Discovery of a treatment to block the progression of multiple sclerosis

May 20, 2015
A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called ...

Cancer drug a possible treatment for multiple sclerosis

February 21, 2013
(Medical Xpress)—A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE. The discovery, ...

Receptor variation influences fingolimod efficacy in mouse multiple sclerosis models

June 16, 2016
Multiple sclerosis (MS) is an autoimmune disorder that results in demyelination of neurons. The FDA-approved drug fingolimod (Gilenya, FTY-720) modulates signaling by the bioactive lipid sphingosine-1-phosphate (S1P), which ...

Study shows halting an enzyme can slow multiple sclerosis in mice

April 30, 2012
Researchers studying multiple sclerosis(MS) have long been looking for the specific molecules in the body that cause lesions in myelin, the fatty, insulating cells that sheathe the nerves. Nearly a decade ago, a group at ...

The innate immune system modulates the severity of multiple sclerosis

November 2, 2015
Multiple sclerosis, a debilitating neurological disease, is triggered by self-reactive T cells that successfully infiltrate the brain and spinal cord where they launch an aggressive autoimmune attack against myelin, the fatty ...

Recommended for you

Scientists discover how brain signals travel to drive language performance

June 21, 2018
Effective verbal communication depends on one's ability to retrieve and select the appropriate words to convey an intended meaning. For many, this process is instinctive, but for someone who has suffered a stroke or another ...

Scientists discover fundamental rule of brain plasticity

June 21, 2018
Our brains are famously flexible, or "plastic," because neurons can do new things by forging new or stronger connections with other neurons. But if some connections strengthen, neuroscientists have reasoned, neurons must ...

Researchers find mechanism behind choosing alcohol over healthy rewards

June 21, 2018
A new study links molecular changes in the brain to behaviours that are central in addiction, such as choosing a drug over alternative rewards. The researchers have developed a method in which rats learn to get an alcohol ...

Waking up is hard to do: Prefrontal cortex implicated in consciousness

June 21, 2018
Philosophers have pondered the nature of consciousness for thousands of years. In the 21st century, the debate over how the brain gives rise to our everyday experience continues to puzzle scientists. To help, researchers ...

'Antifreeze' molecules may stop and reverse damage from brain injuries

June 21, 2018
The key to better treatments for brain injuries and disease may lie in the molecules charged with preventing the clumping of specific proteins associated with cognitive decline and other neurological problems, researchers ...

Study on instinctive behaviour elucidates a synaptic mechanism for computing escape decisions

June 21, 2018
How does your brain decide what to do in a threatening situation? A new paper published in Nature describes a mechanism by which the brain classifies the level of a threat and decides when to escape.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.